Full kits
Everything to say about each page, and what never to.
22 full kits and 20 shorter ones. Open the page you are writing about: who lands there, a hook for each channel, the lines to use, the lines that end the partnership, and your tagged link.
Not sure which page? Browse them as cards instead.
The 22 destinations
Twenty-two pages, twenty-two complete kits.
Every kit carries the same structure, generated from one data file: who lands there, the belief the page changes, four channel hooks, the say-this and never-this pair, the compliant CTA, your tagged link and the disclosure. No status is written into any kit — adjacency warnings read the tracker live.
Hubs and education
Twenty more destinations, abbreviated.
Same perimeter, less scaffolding. Each carries the angle that works and the one rule that page attracts trouble on.
The full catalogue, one page, with each entry's own status.
Hub page — never summarise multiple molecules into one status sentence.
The route, the review, the pricing, no euphemism.
No performance claims of any kind.
The door for the whole women's lane.
Reclamation framing, never vanity, never before/after.
Two doors: full-dose and the microdose route.
Never describe either door by amount.
Measurement before molecule.
“Reverse aging” is banned outright.
Where the demand is unsellable and honest.
Every recovery peptide named here is gated. Status card only.
Plain clinical language beats every euphemism.
PT-141 is gated; do not bring it into the hook.
The most-searched, least-sellable name in the category.
Education only. No availability language in any form.
The second half of the recovery search volume.
Education only. No availability language in any form.
Topical and injectable are different regulatory pathways.
Never merge the two forms into one status.
A green-verdict molecule with real provenance.
Withdrawn in 2008 for commercial reasons — say so accurately or not at all.
The comparison the forums argue about, graded.
Both are gated. Compare evidence, never access.
The dated regulatory board. The strongest link asset we have.
Never summarise the board into one sentence.
Our dated record, with primary sources.
Point at journalism; do not restate a verdict from memory.
Get told when a verdict changes.
Education and waitlist only.
Fifty-four monographs, no dosing in any of them.
No dosing fields exist. Never add one in your own summary.
Combinations, graded, with the weak evidence labelled.
A stack is not a prescription. Never publish one as instructions.
The pharmacy-category distinction, explained once, properly.
Pure education. Nothing here may read as an offer.
A checklist that names nobody, including where we fail it.
Do not turn it into a competitor attack.
Method, not outcome. The honest framing does the persuading.
Evidence grade is never a traffic-light colour.
The catalyst calendar
Publish two weeks before the date, not the day after.
Regulatory dates create search spikes. The traffic goes to whoever was already ranking when the spike arrived. These are the events we can see coming, with the date to publish by and the angle that is already cleared.
What the second advisory batch is reviewing, and why a recommendation would still not be approval.
The six recommended in July 2026 and what rulemaking actually has to do before anything changes.
What the shortage-exception pathway is, and why it is not the same as approval.
One year on: six recommended, one declined, and what has and has not changed since.
Dates track the tracker and move when it moves. Subscribe at /fda-tracker-alerts and you will hear about a change before your comments section does.
Playbooks
The unsellable-demand play, and four others.
The unsellable-demand playbook. BPC-157 and TB-500 are among the most-searched names in this entire category and among the least sellable — both are gated, and neither can be described as obtainable by anyone, including us. Most affiliates therefore skip them, which is why the volume sits there unclaimed.
The play: take the query, send it to the symptom page rather than a product page, embed the live status card so the post stays accurate without you, and let attribution do the rest. Your tag holds site-wide for the cookie window — the reader who arrives on an unsellable molecule and subscribes to something else entirely, inside the window, still credits you. That deferred attribution is the whole reason this traffic is worth writing for.
Steal this post
One publish-ready structure per lane.
Most approved partners never launch because the first asset is the hard part. Here is the first asset, three formats, already inside the perimeter. Edit into your own voice; do not edit out the disclosure timing.
Women's longevity
Blog post
800 words · “Nobody told me perimenopause would change my body composition” — open on the reader's own sentence, name the physiological shift, describe what a proper intake asks, close on the clinician gate. No molecule named above the fold.
Video script
60s · 0–3s: on-screen “#ad — paid partnership with Peptós.LIFE” + spoken. 3–15s: the dismissal she has already heard. 15–40s: what actually changed. 40–55s: what a proper intake asks. 55–60s: the compliant CTA.
Email sequence
5 emails · (1) “That's just menopause” is a description, not a diagnosis · (2) What a proper intake asks · (3) Why hormonal context changes the plan · (4) Named clinicians, third-party testing, published pricing · (5) The founding list, plainly.
Metabolic / weight
Blog post
800 words · “Everyone is selling the same molecules” — the commodity argument, then the path argument: clinician, monitoring, maintenance phase, all-in pricing. Compounded-not-FDA-approved stated in the body, not a footnote.
Video script
60s · 0–3s: disclosure on screen and spoken. 3–12s: three providers, three first-month prices. 12–35s: what month four costs and why nobody shows it. 35–55s: what to ask any provider. 55–60s: CTA.
Email sequence
5 emails · (1) Ask what month four costs · (2) The maintenance phase nobody sold you · (3) Compounded is not FDA-approved, and what that means · (4) How to read a provider's pricing page · (5) The founding list.
Recovery
Blog post
800 words · “The recovery peptide threads leave out the only part that matters” — evidence grade and regulatory status as two separate questions, with a live status embed for each molecule named. Zero availability language throughout.
Video script
60s · 0–3s: disclosure. 3–15s: the forum claim. 15–40s: what the July 2026 recommendation did and did not do. 40–55s: where to check the current position yourself. 55–60s: CTA to the tracker.
Email sequence
5 emails · (1) A recommendation is not an approval · (2) Evidence grade, explained · (3) The two signals and why they disagree · (4) How to check a status yourself · (5) Get told when it changes.
Longevity / energy
Blog post
800 words · “There is no single longevity stack” — method over shopping list, with weak evidence labelled weak. The grading method is the persuasion.
Video script
60s · 0–3s: disclosure. 3–15s: half your stack has one small trial behind it. 15–40s: how to grade a claim. 40–55s: measurement before molecule. 55–60s: CTA.
Email sequence
5 emails · (1) Measurement before molecule · (2) How we grade, and where we say the evidence is thin · (3) What biological age can and cannot tell you · (4) Reading a monograph properly · (5) The founding list.
Sexual health
Blog post
800 words · “The awkward part is the marketing, not the medicine” — plain clinical language, the intake as medical screening, published pricing, no euphemism anywhere.
Video script
60s · 0–3s: disclosure. 3–15s: why the category's marketing is embarrassing and the medicine is not. 15–40s: what the clinician actually reviews. 40–55s: how to tell a legitimate provider. 55–60s: CTA.
Email sequence
5 emails · (1) Plain language, no euphemism · (2) What the intake questions are for · (3) The clinical difference between the two medicines · (4) Published pricing · (5) The founding list.
Which page for which question
Reader question in, destination out.
The biggest earnings killer in affiliate marketing is sending everyone to the homepage. Match the question to the page and the same traffic converts several times better.
- Pick one lane. Not three. The partners who ship pick one.
- Publish one asset from the steal-this-post library for that lane, edited into your own voice inside the perimeter.
- Embed one live status card on the molecule your audience names most — that is the asset that keeps earning after you stop editing.
- Set one alert at /fda-tracker-alerts so a verdict change reaches you before it reaches your comments.
The queries our 22 destinations already rank for, and the ones they do not, published at the JSON twin under keyword_gaps. Write the complementary article and link in — a partner ranking a supporting page is worth more to both of us than a partner competing with ours for the same result.
One pre-rendered, on-brand image per destination at /og/{slug}.png — 1200×630, the headline, the promise and the proof cues, already inside the perimeter. Creators reuse whatever image is easiest to find, so ours is the easiest to find. Grab one from any kit above.
/fda-tracker/news/rss.xml — our dated newsroom as a feed you can auto-post from, partner-tagged. Add ?partner={id} and every syndicated link carries your attribution.
Drag Peptós check to your bookmarks bar, or copy it above and save it as a bookmark by hand. Run it on any draft and it returns which of the six rules the copy breaks. Same banned-terms list as the link builder, in your own drafting tool.
No data yet. Consults are not open, so there is nothing honest to put here. This board fills in once there is a real distribution to show, and we will publish it rather than describe it.
Changelog
What changed in the kit, and when.
New destinations, changed verdicts, retired angles. If you used a live embed you are already covered; if you used a screenshot, this is where you find out it needs replacing. Subscribe at /fda-tracker-alerts.
- Toolkit split into four pages: pick a page, get a link, the full kits, live widgets. The single 13-section scroll gave every section the same weight, so nothing read as more important than anything else.
- The 22 destinations are now cards you can scan, filter and search, colour-coded by category — the first thing on the page instead of the fourth.
- Copy rewritten in plain English throughout. Internal names (the lane router, the perimeter, the two-signal law) are gone from the reader-facing text.
- Added a paste-your-caption checker on the link page, running the same list as the link builder.
- Toolkit published: 22 destination kits, five widgets, the link builder and the compliance validator.
- Tracker resynced after the PCAC close. Every kit's adjacency warning re-derived; no kit copy changed, because no kit hard-codes a status.
- PCAC concluded: six of seven recommended, DSIP declined. All seven verdict dots remain amber.
- Retired every “decision expected” angle — the decision was advisory and rulemaking is pending.
Execution questions
How to ship, not how the programme works.
Programme terms, commissions and eligibility are on /partners.
Do I need approval before I publish?
No. Everything on this page is pre-cleared. Use the hooks, the say-this lines and the compliant CTA as written and you are inside the perimeter. Write your own anchor text and the link builder will check it before you copy it.
Can I edit the hooks?
Yes, within the perimeter. The six rules on the compliance standard govern, not these exact sentences. If your edit adds an availability, legality, FDA-approval or dosing word, the validator will catch it — paste it in before you publish.
What am I actually being credited for right now?
A founding-list signup at /waitlist. Consults are not open, so nothing is transactable. Your tag holds site-wide for the cookie window, including on the tracker and Knowledge Base pages, and the flat CPA applies from first subscription once consults open.
Why is there no commission number on this page?
Because we have not set one, and publishing a rate we have not set would be the exact kind of claim this whole programme tells you not to make. Rates are set in your partner agreement.
The tracker changed a verdict. Do I have to update my old posts?
If you used a status embed, no — it re-reads the feed on every page view and updates itself. If you used a screenshot, yes, and this is the argument for using the embed. Subscribe at /fda-tracker-alerts and you will be told when something moves.
Can I write about BPC-157 at all?
Yes, extensively. You may explain what it is, what the evidence says, and exactly where its regulatory status stands. You may not say, imply, hint or joke that it can be obtained. The status card is the safest way to reference it, because it renders the current position rather than your memory of it.
Do the widgets need an API key?
No. They read public CC BY 4.0 feeds. Attribution and a link back are the licence terms. If the feed is unreachable the widget degrades to a plain branded link rather than rendering anything stale.
Can I run paid search?
Non-brand terms only. Bidding on our name, trademarks, or close misspellings ends the relationship. The full prohibited-traffic list is on the compliance standard.
Last reviewed · every molecule status on this page is read from tracker data at page load, never authored here · machine-readable twin at /partners/affiliate-toolkit.json · Peptós.LIFE · Not medical advice.
Not sure if your wording is allowed?
Paste it into the checker on the link page. It names the rule and suggests a fix.
Check my wordingWant the rules in full?
Every rule with a right and a wrong example, plus the FTC disclosure copy.
The compliance standardStill stuck?
Ask us. A question costs nothing; a post we have to ask you to take down costs both of us.
partners@peptos.life